<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756352</url>
  </required_header>
  <id_info>
    <org_study_id>2012P002678</org_study_id>
    <nct_id>NCT01756352</nct_id>
  </id_info>
  <brief_title>FET-PET for Evaluation of Response of Recurrent GBM to Avastin</brief_title>
  <official_title>Assessment of the Utility of the Radiotracer &quot;FET&quot;in PET Imaging of Recurrent Glioblastoma Multiforme (GBM): Monitoring Early Response to Antiangiogenic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcelo F. Di Carli, MD, FACC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET
      will predict durable benefit in patients receiving anti-angiogenic benefit for presumed
      recurrent GBM (i.e. progression-free survival and overall survival). We have defined one
      primary specific aim, for which we expect to obtain definitive results, and two secondary
      aims, under which we plan to generate preliminary data to support a future, larger project.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PET radiotracer FET provides a measure of large, neutral amino acid transport. This
      transport is significantly upregulated in malignant brain tumors. FET rarely gives false
      positive findings in the setting of inflammation seen after high dose chemotherapy or
      radiotherapy. FET labels low-grade as well as high-grade gliomas, in contrast to FDG, which
      almost exclusively labels only high-grade gliomas. FET imaging may prove to be particularly
      useful in the setting of infiltrative tumor, which is not contrast-enhancing on MRI and
      therefore not detectable with FDG. Management of glioblastoma patients with stable
      contrast-enhancing disease on MRI but increased signs of edema is difficult. This is because
      it is difficult to distinguish simple edema from infiltrative tumor. The former is managed
      with steroids and the latter is managed with chemotherapy, and anti-angiogenic drugs.

      FET may be particularly useful in assessing changes after GBM patients receive anti-vascular
      agents such as Avastin. Avastin is very commonly used in patients after failure of first-line
      treatment in GBM. Not only is Avastin costly, but it also can have serious side effects such
      as internal bleeding and gastric perforation, severe hypertension, poor wound healing, and
      renal toxicity. It is important to know when a patient is failing Avastin treatment so that
      the drug can be discontinued. Preliminary data in Europe (see figures below) suggests that
      FET-PET can accurately distinguish Avastin responders from non-responders.

      Inclusion Criteria:

        1. GBM patients with changes on MRI suggestive of recurrence who have not yet initiated
           antiangiogenic therapy.

        2. Age ≥ 18

        3. Anticipated survival &gt;3 months

        4. Able to give informed consent

        5. Capable of undergoing scan without the need for sedation or general anesthesia.

      Exclusion Criteria:

        1. Active intracranial infection or nonglial brain mass.

        2. Recent large intracranial hemorrhage (&lt;1 month; size to be determined by principal
           investigator)

        3. Pregnant or nursing. Quantitative serum hCG testing will be performed prior to the
           initial and each -subsequent FET- PET scan on all females of childbearing potential. Our
           BWH Radiation Safety Committee and Partners IRB requires stat serum ß-hcG pregnancy
           tests.

        4. Patient lives too far from BWH and/or is unwilling/ unable to return for scheduled
           imaging visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 13, 2015</completion_date>
  <primary_completion_date type="Actual">September 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From date of baseline PET scan until the date of death from any cause, assessed up to 2 years.</time_frame>
    <description>The primary objective is to assess the utility of FET-PET imaging for prediction of progression-free survival in recurrent glioblastoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of baseline PET scan until the date of death from any cause, assessed up to 2 years.</time_frame>
    <description>The secondary objective is to assess the utility of FET-PET imaging for prediction of overall survival in recurrent glioblastoma.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>GBM</condition>
  <arm_group>
    <arm_group_label>GBM Avastin receiving 18F-FET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FET</intervention_name>
    <description>Radiotracer, surrogate marker for protein synthesis</description>
    <arm_group_label>GBM Avastin receiving 18F-FET</arm_group_label>
    <other_name>18F-Fluoroethyltyrosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. GBM patients with changes on MRI suggestive of recurrence who have not yet
             initiated antiangiogenic therapy. 2. Age ≥ 18 3. Anticipated survival &gt;3 months 4.
             Able to give informed consent 5. Capable of undergoing scan without the need for
             sedation or general anesthesia.

        Exclusion Criteria:

          1. Active intracranial infection or nonglial brain mass.

          2. Recent large intracranial hemorrhage (&lt;1 month; size to be determined by principal
             investigator)

          3. Pregnant or nursing. Quantitative serum hCG testing will be performed prior to the
             initial and each -subsequent FET- PET scan on all females of childbearing potential.
             Our BWH Radiation Safety Committee and Partners IRB requires stat serum ß-hcG
             pregnancy tests.

          4. Patient lives too far from BWH and/or is unwilling/ unable to return for scheduled
             imaging visits.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond L Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2012</study_first_posted>
  <results_first_submitted>September 12, 2019</results_first_submitted>
  <results_first_submitted_qc>October 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Marcelo F. Di Carli, MD, FACC</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine/PET</investigator_title>
  </responsible_party>
  <keyword>FET</keyword>
  <keyword>Fluoroethyl tyrosine</keyword>
  <keyword>GBM</keyword>
  <keyword>Response to treatment</keyword>
  <keyword>Avastin</keyword>
  <keyword>Brain Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GBM Avastin Receiving 18F-FET</title>
          <description>Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
18F-FET: Radiotracer, surrogate marker for protein synthesis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>moved away and lost to followup</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GBM Avastin Receiving 18F-FET</title>
          <description>Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
18F-FET: Radiotracer, surrogate marker for protein synthesis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" lower_limit="18" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>The primary objective is to assess the utility of FET-PET imaging for prediction of progression-free survival in recurrent glioblastoma.</description>
        <time_frame>From date of baseline PET scan until the date of death from any cause, assessed up to 2 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GBM Avastin Receiving 18F-FET</title>
            <description>Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
18F-FET: Radiotracer, surrogate marker for protein synthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The primary objective is to assess the utility of FET-PET imaging for prediction of progression-free survival in recurrent glioblastoma.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.25" spread="161.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The secondary objective is to assess the utility of FET-PET imaging for prediction of overall survival in recurrent glioblastoma.</description>
        <time_frame>From date of baseline PET scan until the date of death from any cause, assessed up to 2 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GBM Avastin Receiving 18F-FET</title>
            <description>Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
18F-FET: Radiotracer, surrogate marker for protein synthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The secondary objective is to assess the utility of FET-PET imaging for prediction of overall survival in recurrent glioblastoma.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.58" spread="222.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of baseline PET scan until the date of death from any cause, assessed up to 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GBM Avastin Receiving 18F-FET</title>
          <description>Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
18F-FET: Radiotracer, surrogate marker for protein synthesis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcelo DiCarli, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>(617) 732-6290</phone>
      <email>mdicarli@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

